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ABSTRACT:
Mutations in the critical chromatin modifier ATRX and mutations in CIC and FUBP1, 
which are potent regulators of cell growth, have been discovered in specific subtypes 
of gliomas, the most common type of primary malignant brain tumors. However, the 
frequency of these mutations in many subtypes of gliomas, and their association with 
clinical features of the patients, is poorly understood. Here we analyzed these loci in 
363 brain tumors. ATRX is frequently mutated in grade II-III astrocytomas (71%), 
oligoastrocytomas (68%), and secondary glioblastomas (57%), and ATRX mutations 
are associated with IDH1 mutations and with an alternative lengthening of telomeres 
phenotype. CIC and FUBP1 mutations occurred frequently in oligodendrogliomas 
(46% and 24%, respectively) but rarely in astrocytomas or oligoastrocytomas 
(<10%). This analysis allowed us to define two highly recurrent genetic signatures 
in gliomas: IDH1/ATRX (I-A) and IDH1/CIC/FUBP1 (I-CF). Patients with I-CF 
gliomas had a significantly longer median overall survival (96 months) than patients 
with I-A gliomas (51 months) and patients with gliomas that did not harbor either 
signature (13 months). The genetic signatures distinguished clinically distinct groups 
of oligoastrocytoma patients, which usually present a diagnostic challenge, and 
were associated with differences in clinical outcome even among individual tumor 
types. In addition to providing new clues about the genetic alterations underlying 
gliomas, the results have immediate clinical implications, providing a tripartite genetic 
signature that can serve as a useful adjunct to conventional glioma classification 
that may aid in prognosis, treatment selection, and therapeutic trial design.
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INTRODUCTION
Gliomas are the most common primary tumors 
of the central nervous system. They are classified as 
grade I to grade IV on the basis of histological criteria 
established by the World Health Organization (WHO) 
[1]. Besides grading, gliomas are further classified into 
subtypes of which the most common include astrocytomas 
and oligodendrogliomas. Grade I gliomas are usually 
benign and operable, and rarely progress to higher-grade 
gliomas.  Grade II astrocytomas and oligodendrogliomas 
can progress to grade III anaplastic astrocytomas and 
anaplastic oligodendrogliomas, respectively. Grade 
III gliomas are generally incurable and have a median 
survival of 3-10 years. Glioblastomas (GBMs) are grade 
IV astrocytomas including mainly “primary GBMs” 
(95%) that arise de novo, and “secondary GBMs” that 
have progressed from clinically discernible grade II or III 
astrocytomas. Grade II-III oligoastrocytomas are a subset 
of gliomas that present with an appearance of mixed glial 
cell origin, astrocytoma and oligodendroglioma [1]. These 
“mixed gliomas” are particularly difficult to diagnose and 
their interpretation is often subjective and varies between 
different pathologists [1-3]. 
Recent research has begun to characterize the 
molecular landscape of gliomas to better understand their 
molecular pathogenesis and to aid in their classification 
for clinical management. High-throughput molecular 
studies by The Cancer Genome Atlas and other groups 
have focused on the more common and lethal grade IV 
GBMs and identified molecular subgroups of those tumors 
[4-8]. Major findings include frequent activating mutations 
in isocitrate dehydrogenase genes, IDH1 and IDH2 
(“IDH mutation” refers to a mutation in either gene), in 
secondary GBMs (>50%) and rarely in primary GBMs 
(<5%) [5, 9-12]. Additionally, inactivating alterations 
in Alpha Thalassemia/Mental Retardation Syndrome 
X-linked (ATRX) were recently identified in 7% of adult 
GBMs and in 14-31% of pediatric GBMs [13, 14]. ATRX 
is critical for normal telomere homeostasis by regulating 
incorporation of histone variant H3.3 into telomeric 
chromatin [15-17], and ATRX alterations are associated 
with an alternative lengthening of telomeres (ALT) 
phenotype among GBMs [13, 14]. Recent GBM exome 
sequencing studies also confirmed frequent mutations in 
the tumor suppressor gene TP53 among secondary GBMs 
(65%), and less frequently in primary GBMs (28%) [5, 6, 
14, 18].  
The molecular properties of grade II-III gliomas 
are less well-characterized than grade IV GBMs. Lower-
grade gliomas share molecular features with secondary 
GBMs and with a subset of primary GBMs, including 
frequent IDH mutations (>70%) [10, 12, 19], a proneural 
gene expression signature [6, 7, 20], and a glioma CpG 
island hypermethylator phenotype (G-CIMP) [8]. Grade 
II-III astrocytomas frequently harbor TP53 mutations, 
which are uncommon in oligodendrogliomas [3, 10].  ALT 
occurs frequently in grade II-III astrocytomas (63%) but 
less commonly in oligodendrogliomas (20%) [21-24]. 
However, whether ATRX mutations occur in adult grade 
II-III astrocytomas, and whether they may associate with 
ALT in those tumors, remains unknown.
Co-deletion of chromosomal arms 1p and 19q 
is a well-known prognostic marker found frequently 
(>60%) in grade II-III oligodendrogliomas [25-27]. 
Recent exomic sequencing of oligodendrogliomas 
revealed inactivating mutations in two tumor suppressor 
genes: homolog of Drosophila capicua (CIC) and far-
upstream binding protein 1 (FUBP1) in 53% and 15% 
of oligodendrogliomas, respectively [28-30]. Since 
CIC is located on chromosomal arm 19q and FUBP1 is 
located on chromosomal arm 1p, 1p/19q loss is thought 
to be a mechanism to inactivate CIC and FUBP1 [28]. 
Among grade II-III gliomas, CIC and FUBP1 mutational 
status has only been investigated in oligodendrogliomas, 
oligoastrocytomas and preselected astrocytomas with 19q 
loss [30].
Given the difficulty in classifying gliomas, in 
particular grade II-III gliomas, we sought to characterize 
the landscape of genetic alterations in numerous common 
subtypes of brain tumors.  We focused on both alterations 
that have been discovered recently in at least one glioma 
subtype by high-throughput molecular analyses (ATRX, 
CIC, FUBP1) and on classic alterations (IDH, TP53, 
1p/19q) that could be routinely detected in a molecular 
genetics laboratory. This analysis uncovered frequent 
alterations in ATRX, CIC, and FUBP1 in new glioma 
subtypes and identified an association between ATRX 
alterations and ALT in grade II-III gliomas. The mutational 
pattern identified here also revealed mutually exclusive, 
highly recurrent, multi-gene mutational signatures that 
correlated well with the clinical features of the patients.
RESULTS
ATRX inactivation is linked to mutations in TP53 
and IDH, and to altered telomeres
ATRX alterations were found in 93 out of 363 brain 
tumors, in ten tumor subtypes (Table 1). ATRX alterations 
occurred frequently in grade II astrocytomas (67%, 
n=15), grade III astrocytomas (73%, n=44), secondary 
GBMs (57%, n=14), and in tumors of mixed astrocytic 
and oligodendrocytic lineage (68%, n=40). In contrast, 
ATRX alterations were rare in primary GBMs (4%, n=94) 
and uncommon in pediatric GBMs (20%, n=25) and pure 
oligodendroglial tumors (14%, n=50). Surprisingly, while 
all of the ATRX mutations in pediatric GBMs were found 
near the carboxy-terminal Helicase domain as observed 
previously [14, 31], mutations in adult gliomas instead 
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Figure 1: Distribution of ATRX, CIC, and FUBP1 mutations in gliomas. Schematics of the coding sequences of ATRX, 
CIC, and FUBP1 are shown. Mutations were predominantly truncating mutations such as frameshifts (shaded triangles) and nonsense 
mutations (shaded circles). Empty circles correspond to missense mutations. ATRX contains a DNA-binding ATRX-DNMT3-DNMT3L 
(ADD) domain and an ATPase Helicase Domain. ATRX alterations occurred in 20% of pediatric GBMs (n=25) and all of those mutations 
clustered in the Helicase domain of ATRX as described previously [14]. ATRX mutations in adult gliomas instead distributed evenly.  CIC 
contains four highly conserved domains, the HMG (high mobility group) box responsible for DNA binding and proline-rich (pro-rich) 
domains. Among CIC mutations (n=29), a predilection for missense mutations occurred in the HMG box domain (24%). Mutations in 
FUBP1 (n=16) occurred 3’ of the N-terminal α-helix domain, which controls binding of FUBP1 to the FBP-interacting repressor (FIR). 
Gene representations are to scale.
      
ADD C-terminal  
Helicase 
              
11-gly 
repeat 
KH1 N-terminal 
α-helix 
KH2 KH3 KH4 
  
            
  
  
  
  
  
      
  
FUBP1 
ATRX 
  
  
  
  
  
  
    
  
  
  
SNF2 Helicase 
  
  
  
  
  
  
  
  
  
  
  
    
  
  
  
  
    
  
  
  
  
  
  
  
  
  
  
  
  
      
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
  
  
    
  
  
  
      
  
  
  
  
  
  
          
Pro-rich 
        
  
                          
  
Pro-rich Pro-rich HMG Box 
  
  
  
  
  
  
  
  
    
CIC 
Oncotarget 2012; 3:  710-722712www.impactjournals.com/oncotarget
distributed evenly (Figure 1 and Supplementary Table 1).
The association between ATRX alterations and other 
frequent molecular alterations was analyzed among the 
grade II-IV gliomas (Figure 2 and Supplementary Fig. 1). 
IDH mutations were observed in 87 of 88 adult gliomas 
with an ATRX alteration (99%). We termed tumors with 
this genetic signature “I-A gliomas”, denoting that these 
tumors had alterations in either IDH1 or IDH2 and in 
ATRX.  Most I-A adult gliomas also had mutations in TP53 
(94%, n=87), and the majority of adult gliomas with TP53 
mutations had the I-A signature (72%, n=113). The I-A 
signature was tightly associated with ALT among grade 
II-III gliomas (n=71): 100% (49/49) of gliomas with ALT 
were I-A, and 98% (49/50) of gliomas with I-A were ALT 
positive (P<0.001, Figure 3). ATRX alterations and 1p/19q 
loss rarely co-occurred (only one case, P<0.001). 
CIC and FUBP1 mutations are linked to IDH 
mutation and 1p/19q loss 
Sequencing analysis of CIC and FUBP1 genes in the 
same brain tumors revealed 29 and 16 somatic mutations, 
respectively (Figure 1 and Supplementary Table 1). 
The highest frequency of CIC and FUBP1 mutations 
occurred in grade II (38% and 14%, n=21) and grade III 
oligodendrogliomas (52% and 31%, n=29). In contrast, 
CIC and FUBP1 mutations were rare in primary GBMs 
(1% and 2%, n=94) and completely absent (0%, n=59) 
in grade II-III pure astrocytic tumors. Seven tumors had 
concurrent CIC and FUBP1 mutations. Every glioma 
with a CIC or an FUBP1 mutation exhibited an IDH gene 
mutation (Figure 2 and Supplementary Fig. 1). Almost 
every glioma with a CIC or an FUBP1 mutation exhibited 
loss of both chromosomes 1p and 19q (98%, n=36). 
Therefore, we termed tumors that had mutations in IDH1 
or IDH2 combined with either 1p/19q loss, CIC mutation, 
or FUBP1 mutations as “I-CF gliomas.” CIC and FUBP1 
mutations were mutually exclusive with ATRX or TP53 
mutations (P<0.001 for all four comparisons).
For the purposes of this study, other adult gliomas 
that did not fall into the I-A or I-CF signatures were 
categorized as I-X gliomas (i.e. not I-A or I-CF). Nearly 
half of adult gliomas included in this study (47%, n=257) 
were classified as I-X gliomas. Seventy-four percent of 
the I-X gliomas were diagnosed as grade IV primary 
GBMs and 95% of primary GBMs were classified as 
I-X gliomas. Most, but not all I-X gliomas (87%) were 
IDH wild type. Mutant TP53 was found in 26% of these 
tumors, and most of the I-X gliomas with IDH mutations 
(69%) also had TP53 mutations. Seven percent of adult 
gliomas were ATRX mutant or showed loss of 1p and 19q 
and were considered I-X gliomas because they lacked IDH 
mutations. 
Table 1: Frequency of mutations in 13 tumor types
IDH ATRX TP53 CIC FUBP1
Tumor Classification
No. of 
tumors 
analyzed
Mean 
age 
(yrs.)
Median 
age 
(yrs.)
Male 
Sex (%)
Mut 
No.
%
Mut 
No.
%
Mut 
No.
%
Mut 
No.
%
Mut 
No.
%
Astrocytic tumors 203 37 26 54% 71 35% 59 29% 91 45% 1 0.50% 2 1%
Pilocytic Astrocytoma (grade I) 9 7 4 56% 0 0% 0 0% NA NA 0 0% 0 0%
Pleomorphic xanthoastrocytoma 
(grade II)
2 11 11 0% 0 0% 0 0% 2 100% 0 0% 0 0%
Astrocytoma (grade II) 15 25 30 60% 10 67% 10 67% 9 60% 0 0% 0 0%
Anaplastic Astrocytoma (grade III) 44 36 35 61% 37 84% 32 73% 36 82% 0 0% 0 0%
Secondary Adult glioblastoma 
(grade IV)
14 37 36 64% 8 57% 8 57% 11 79% 0 0% 0 0%
Adult glioblastoma (grade IV) 94 56 57 60% 13 14% 4 4% 22 23% 1 1% 2 2%
Pediatric glioblastoma (grade IV) 25 12 12 79% 3 12% 5 20% 11 44% 0 0% 0 0%
Oligodendroglial 50 40 41 55% 46 92% 7 14% 7 14% 23 46% 12 24%
Oligodendroglioma (grade II) 21 36 35 48% 18 86% 5 24% 5 24% 8 38% 3 14%
Anaplastic Oligodendroglioma 
(grade III)
29 43 46 62% 28 96% 2 7% 2 7% 15 52% 9 31%
Oligoastrocytic (Mixed) 40 41 38 58% 39 98% 27 68% 27 68% 3 8% 2 5%
 Oligoastrocytoma (grade II) 18 42 39 61% 18 100% 10 56% 11 61% 1 6% 1 6%
Anaplastic  Oligoastrocytoma 
(grade III)
22 40 37 55% 21 95% 17 77% 16 73% 2 9% 1 5%
Ependymoma (grade II) 5 NA NA NA 0 0% 0 0% NA NA 0 0% 0 0%
Medulloblastoma (grade IV) 65 9 7 54% 0 0% 1 2% 1 NA 2 3% 0 0%
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Pathologic and clinical characteristics of I-A, I-CF 
and I-X gliomas 
On the basis of the mutational patterns described 
above, gliomas could be classified as either I-A, I-CF, or 
I-X. We sought to determine whether these glioma genetic 
signatures were associated with any differences between 
the clinical characteristics of the patients who bore the 
tumors. Survival, age at diagnosis, and histopathological 
diagnosis data were collected for 199 grade II-IV adult 
glioma patients, including a cohort of glioma patients 
from the United States (n=156 patients) and a cohort 
of glioma patients from Brazil (n=43 patients). Age, 
median survival, and histopathological diagnosis of 
patients with I-A, I-CF, and I-X tumors were similar in 
the two cohorts (Supplementary Table 2). Distribution 
of genetic signatures among the combined cohort of 199 
patients is shown in Table 2 and was as follows: gliomas 
classified as astrocytic were primarily I-A (32%) or I-X 
(66%) and rarely carried the I-CF (2%) genetic signature. 
Oligodendroglial tumors were primarily I-CF (77%) but a 
significant proportion harbored the I-A (16%) or I-X (7%) 
genetic signatures. 
Age at diagnosis and survival parameters were first 
analyzed among the group of 199 grade II-IV glioma 
patients, and then among subgroups of patients with 
specific tumor types. At the time of diagnosis, patients 
with I-A gliomas were younger (mean age of 34) than 
patients with I-CF tumors (mean age of 44, P<0.001) and 
patients with I-X tumors (mean age of 54, P<0.001). This 
stratification in age was independent of tumor grade, as 
patients with I-A tumors were younger than patients with 
the other two signatures among the group of grade III 
patients (34, 46, and 46 years old, P<0.001) and the group 
of grade IV patients (29, 53, and 55 years old, P<0.001).  
Among all grade II-IV glioma patients, those 
whose tumors bore the I-A and I-CF signatures survived 
longer than those with I-X tumors (median 51, 96, and 
13 months, P<0.001) (Figure 4). Even when stratified 
by grade, patients whose tumors bore the I-A and I-CF 
signature survived longer than patients with the I-X 
signature among the subgroup of grade III gliomas 
(median 51, 127, and 22 months, P<0.001, Figure 4). 
In contrast, there was not a significant difference in 
survival between groups of grade III gliomas that were 
stratified by standard histopathological diagnostic criteria 
(P=0.37, log-rank test, Figure 4). I-A patients also 
Figure 2: Distribution of ATRX, TP53, IDH, CIC, and FUBP1 mutations, and of chromosomes 1p and 19q loss, in 
grade II-IV gliomas. Data are from 15 grade II astrocytomas (AII), 44 grade III astrocytomas (AIII), 21 grade II oligodendrogliomas 
(OII), 29 grade III oligodendrogliomas (OIII), 18 grade II oligoastrocytomas (OAII), 22 grade III oligoastrocytomas (OAIII), 14 secondary 
GBMs (2° GBM), 94 primary GBMs (1° GBM), and 25 pediatric GBMs. chromosome 1p status is indicated in the top of the lower row, and 
chromosome19q status is indicated in the bottom of this cell, with yellow coloring indicating loss of the indicated chromosomal arm. Gray 
cells denote analyses which were not informative or for which additional genetic material was not available for analysis.
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survived longer than I-X patients among GBMs (median 
31 vs. 13 months, P=0.016,) and among all astrocytomas 
(grade II-IV, median 51 vs. 13 months, P<0.001) 
(Supplementary Fig. 2). Significant differences in median 
survival between I-A, I-CF, and I-X signatures were not 
observed among the grade II glioma patients or grade II-III 
oligodendrogliomas, or between CIC and FUBP1 mutated 
patients (Supplementary Fig. 2). 
IDH mutations are associated with improved survival 
in gliomas [10, 11, 32]. Among all gliomas with IDH 
mutations, patients with IDH mutations in the I-X group 
had a shorter median survival (28 months) than patients 
with I-A tumors (51 months, P=0.007) or I-CF tumors (96 
months, P<0.001) (Figure 4). In the grade III astrocytoma 
group, patients with I-A tumors survived much longer 
(66 months) than patients with IDH-mutated I-X tumors 
(13 months, P=0.002) and IDH wild-type I-X tumors (22 
months, P=0.005) (Figure 4). These results suggest that 
the I-A and I-CF signatures may provide more prognostic 
information than IDH mutational status alone.
I-A and I-CF signatures can discriminate gliomas 
with mixed histopathology
40 gliomas with mixed oligodendrocytic and 
astrocytic histopathology were examined to determine 
their I-A, I-CF, and I-X status (Supplementary Table 3). 
33 of these cases showed incomplete loss at loci on 1p36, 
1p32, and 19q in prior clinical FISH testing and exhibited 
light microscopic appearances that were considered to 
be equivocal between oligodendroglioma or astrocytoma 
based on nuclear morphology and cytologic appearance. 
Greater than half of all mixed histology gliomas were 
I-A (65%), although I-CF (23%) and I-X (10%) genetic 
signatures were also found in this subgroup. In one case, 
the tumor had a “mixed” genetic signature: one grade III 
oligoastrocytoma demonstrated both an ATRX alteration 
and 1p/19q loss. When grouped by genetic signature, the 
age of oligoastrocytoma patients showed the same pattern 
observed for other glioma types: mean age at diagnosis 
was 35 for I-A patients, 49 for I-CF patients, and 59 
Table 2: Characteristics of patients with I-A, I-CF, and I-X genetic signatures 
I-A I-CF I-X p Value*
Age (mean ± S.D., years) 34 ± 7 44 ± 11 54 ± 15 <0.001
       (median, years) 33 46 56
Gender (% male) 56 54 65 0.33
Survival (median, months) 51 96 13 <0.001
All Cases (n=199) 59 (29.6) 39 (19.6) 101 (50.8)
Astrocytomas (n=148) 48 (32.4) 3 (2.0) 97 (65.6)
Oligodendrogliomas (n=44) 7 (15.9) 34 (77.3) 3 (6.8)
Mixed Histology (n=7) 4 (57.1) 2 (28.6) 1 (14.3)
Grade II (n=31) 15 (48.4) 12 (38.7) 4 (12.9)
Grade III (n=69) 34 (49.3) 25 (36.2) 10 (14.5)
Grade IV (n=99) 10 (10.1) 2 (2.0) 87 (87.9)
Secondary GBM (n=12) 7 (58.3) 0 (0.0) 5 (41.7)
IDH Mutant Tumors (n=111) 59 (53.2) 39 (35.1) 13 (11.7)
The 199 patients analyzed above are the subset of all adult (>20 yr) grade II-IV glioma patients 
who had age and survival information
*One-way ANOVA for difference in mean age distribution, Chi-squared test for difference in 
gender proportions, and log-rank test for difference in survival
Oncotarget 2012; 3:  710-722715www.impactjournals.com/oncotarget
for I-X patients (P=0.001). Survival statistics were not 
tabulated because this cohort was only recently collected 
and median follow-up was insufficient.
DISCUSSION
The mutational analysis of 363 brain tumors reported 
here represents the largest effort to date to define the 
distribution of ATRX, CIC, and FUBP1 mutations in 
gliomas. This analysis revealed for the first time to our 
knowledge that ATRX mutations are frequent among grade 
II-III adult astrocytic tumors and are tightly associated 
with an ALT phenotype. The association between ATRX 
mutations with IDH mutations, and the association 
between CIC/FUBP1 mutations and IDH mutations 
as well as 1p/19q loss defined I-A and I-CF genetic 
signatures. These signatures are especially common among 
the grade II-III gliomas and remarkably homogeneous in 
terms of genetic alterations and clinical characteristics. 
I-A tumors were defined by alterations in ATRX and in 
IDH; they almost always had ALT and TP53 mutations, 
typically had an astrocytic histological component, and 
were often diagnosed in the fourth decade of life. I-CF 
tumors were defined by IDH mutations and by alterations 
in either CIC, FUBP1, and/or 1p/19q, rarely displayed 
ALT, typically had an oligodendroglial component and 
were often diagnosed in the fifth decade of life. This 
molecular classification system distinguishes the prognosis 
of gliomas with I-A and I-CF genetic signatures from 
each other and from the poorly-performing, genetically 
heterogeneous I-X group (Figure 5). 
Our mutational analysis expands on recent reports 
that ATRX, CIC, and FUBP1 mutations are frequent 
in specific nervous system tumor types [14, 28-31, 
33]. ATRX mutations were recently found to define a 
clinically distinct population of teenaged and young adult 
neuroblastoma patients, who often had a protracted course 
with death occurring many years after diagnosis [33]. 
Our results reveal striking parallels to the ATRX-mutated 
neuroblastoma patients, since ATRX-mutated glioma 
patients are also relatively young adults and demonstrate 
a protracted but ultimately fatal course (median overall 
survival 51 months). In contrast to a previous report 
that FUBP1 mutations always co-occurred with a CIC 
mutation among a cohort of 18 oligodendrogliomas and 42 
oligoastrocytomas reported by Sahm and colleagues [30], 
we did not observe any significant associations between 
CIC and FUBP1 mutations among 50 oligodendrogliomas 
and 40 oligoastrocytomas (Figure 1). However, we did 
observe a case with CIC mutation that occurred in the 
Figure 3: ALT associates with the ATRX alterations and the I-A signature. (A) representative grade III astrocytoma section 
that was positive for ALT is shown on the left. A nucleus demonstrating large, ultra-bright telomeres (pink) is indicated with the shaded 
arrow. A p53 positive nucleus (green), which reflects p53 dysfunction, is indicated with the empty arrow. A representative image of a grade 
III astrocytoma section that was negative for both ALT and for p53 nuclear staining is shown on the right. The number of tumors with ALT 
and/or ATRX alterations is shown, along with the percentage of each tumor type with ALT. All tumors with ATRX alterations were I-A, that 
is, they also had an IDH mutation (n=50); the remaining tumors were IDH wild-type and did not have an ATRX alteration (n=21).
  
No ATRX 
alteration 
ATRX  
alteration 
ALT-negative 21 1 
ALT-positive 0 49 
Tumor type 
No. with ALT/  
Total analyzed (%) 
Grade II astrocytoma 3/3 (100) 
Grade III astrocytoma 22/29 (76) 
Grade II oligodendroglioma 1/3 (33) 
Grade III oligodendroglioma 0/4 (0) 
Grade II oligoastrocytoma 8/13 (62) 
Grade III oligoastrocytoma 15/19 (79) 
ALT-positive ALT-negative 
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Figure 4: Survival of glioma patients with I-A, I-CF, and I-X genetic signatures. Kaplan-Meier estimates of survival are 
shown for adult glioma patients, with the number of patients at risk at each time point for each group shown below the respective plot. 
Among all adult patients with grade II-IV gliomas (n=199), those with I-A tumors and with I-CF tumors survived significantly longer 
(median 51 and 96 months) than patients with I-X tumors (13 months; P<0.001 for both comparisons). Among grade III glioma patients 
with tumors of all histologies (n=69), there was a significant difference in survival between groups of patients with I-A or I-CF tumors and 
patients with I-X tumors (I-A and I-X, P = 0.002; I-CF and I-X, P<0.001). There was not a significant difference in survival when the same 
grade III glioma patients were stratified by the histopathological diagnosis of their tumors (P=0.37). When all 199 grade II-IV gliomas were 
additionally stratified by IDH status, patients with I-A tumors and patients with I-CF tumors still survived significantly longer (median 51 
and 96 months) than patients with IDH-mutated I-X tumors, and also longer than patients with IDH-WT I-X tumors (median 28 and 13 
months, respectively; P<0.001 for all four comparisons). When grade III astrocytoma patients (n=39) were stratified by genetic signature 
and IDH status of their tumors, patients with I-A tumors survived longer (66 months) than grade III astrocytoma patients with either IDH-
mutated I-X tumors (22 months, P=0.005) and patients with IDH-WT I-X tumors (13 months, P=0.002).
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absence of 1p/19q loss, which is a situation that was 
observed in one oligodendroglial tumor by Sahm and 
colleagues [30]. In addition to expanding on previous 
preliminary reports of the frequency of ATRX, CIC, and 
FUBP1 mutations in selected tumor types, our study 
for the first time identifies associations between these 
mutations and age at diagnosis and clinical outcome 
among glioma patients.
Mutational analysis of ATRX, CIC, and FUBP1 
refined the prognostic information provided by the 
known prognostic markers IDH, TP53, and 1p/19q [1, 
2, 11, 32, 34]. This refinement is shown by comparing 
tumors with isolated IDH mutations to patients who 
had these mutations in the context of a full I-A or I-CF 
genetic signature (Figure 4). 1p/19q status alone also may 
not be sufficient to determine whether a tumor contains 
alterations in CIC or FUBP1, since CIC mutation occurred 
in the absence of 1p/19q alteration in one of the cases 
studied. Also, the presence of an oligoastrocytoma with 
“mixed” I-A and I-CF signatures raises the possibility that 
a subset of histopathologically mixed tumors are truly 
heterogeneous in a manner that may not be detected by 
routine 1p/19q analysis alone. IDH-mutated gliomas are a 
subset of the gliomas with the proneural gene expression 
signature [6], and IDH mutations tightly overlap with 
the G-CIMP hypermethylator phenotype among gliomas 
[8, 35]. Therefore, the I-A and I-CF genetic signatures 
provide a molecular platform to further subclassify the 
broader proneural and G-CIMP molecular subgroups of 
gliomas.
In contrast to the I-A and I-CF genetic signatures, 
which represent homogeneous genetic disease entities, I-X 
tumors are a genetically heterogeneous group. Based on 
their association with poor patient survival and advanced 
patient age, and on their lack of IDH or ATRX mutations, 
I-X tumors are similar to primary GBMs [3, 10, 13] and 
to IDH wild-type low-grade gliomas [36, 37]. Patients 
with these tumors can be further classified into prognostic 
subgroups on the basis of other mutational, copy number, 
gene expression, and DNA methylation alterations such 
as EGFR amplification, PTEN deletion, gene expression 
signatures, and other previously-described markers [3-8]. 
Our genetic classification scheme provides a prognostic 
tool to identify uncommon I-A and I-CF tumors among 
the grade IV gliomas and to classify the vast majority of 
grade II-III gliomas.
Many tumors classified as one glioma subtype 
by histopathological criteria bore hallmark genetic and 
clinical features of another tumor type in the present 
study. 16% (7/39) of oligodendrogliomas and 3% (3/87) 
of primary GBMs bore the I-A genotype, suggesting that 
a subset of tumors diagnosed as oligodendrogliomas or 
primary GBMs are genetically more similar to grade II-III 
astrocytomas. 11% (15/132) of grade II-III gliomas and 
Figure 5: Model for molecular classification of gliomas. Alterations in IDH and ATRX comprise the I-A signature, and alterations 
in IDH as well as one or more of CIC, FUBP1, or combined 1p/19q loss comprise the I-CF signature. I-X gliomas do not have either 
signature and likely represent multiple molecular disease subgroups. The I-A and I-CF signatures arise early in the pathogenesis of a glioma 
from a normal precursor cell. I-CF gliomas are typically grade II-III oligodendrogliomas and patients with these tumors survive for about 8 
years. I-A gliomas are typically grade II-III astrocytomas or grade IV secondary GBMs and patients with these tumors survive for about 5 
years. I-X gliomas are typically grade IV primary GBMs and patients with these tumors survive for about 1 year.
Normal Cell
IDH, ATRX, TP53
I-CF glioma
I-A glioma
I-X glioma
I-CF – tumors mutant in IDH, CIC and/or FUBP1 with 1p/19q
I-A – tumors mutant in IDH and ATRX with altered telomeres (ALT)
I-X – tumors without I-A or I-CF mutations; represents multiple molecular subgroups,
similar to primary GBM
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GBMs lacked I-A or I-CF gene signatures altogether and 
had a poor survival (I-X tumors) and are likely genetically 
more similar to primary GBMs than to other grade II-III 
gliomas. Moreover, 98% (39/40) of gliomas containing 
histopathological features of both oligodendrogliomas 
and astrocytomas could be unambiguously assigned to a 
genetic signature: 26 were I-A, 9 were I-CF, and 4 were 
I-X.  
Currently, there are no significant differences 
in the treatment of gliomas based on astrocytic or 
oligodendrocytic differentiation, or based on any 
molecular prognostic markers. Treatment decisions 
are based on WHO tumor grade [2, 38] despite the fact 
that outcomes vary significantly between different 
glioma subgroups [1, 7, 25, 27]. With the development 
of personalized therapies for glioma patients, a refined 
classification that incorporates genetic signatures may 
become critical for their management. As sequencing 
technology declines in cost, genotypic analysis is expected 
to become increasingly accessible to patients, not only as 
part of clinical trials, but also as part of standard clinical 
care. In the interim, these data suggest that new therapeutic 
trials for patients with gliomas should incorporate genetic 
signatures, as well as histopathologic signatures, to help 
to classify patients for eligibility for a specific treatment 
and to determine their outcomes. Furthermore, the 
identification in this study of genetic alterations that may 
cooperate in driving glioma pathogenesis will inform 
future studies of the molecular mechanism of glioma 
pathogenesis and the design of targeted therapies. 
METHODS
Patient Samples
Snap-frozen tumor tissue and matched blood was 
obtained from patients from The Preston Robert Tisch 
Brain Tumor Center Biorepository at Duke University 
Medical Center (n=291), Johns Hopkins Medical Institutes 
(n=27), and the University of Sao Paulo, Brazil (n=45) 
with informed consent from the patients under protocols 
approved by the Institutional Review Boards of the 
respective instituions. Tissue sections were centrally 
reviewed by board-certified neuropathologists to ensure 
that ≥ 95% of the section consisted of tumor cells and to 
confirm histopathological diagnosis. DNA was extracted 
from snap-frozen tissue obtained from primary brain 
tumors or from xenografts that were serially passaged in 
mice that were derived from primary brain tumors.  All 
samples were obtained in accordance with the Health 
Insurance Portability and Accountability Act (HIPAA). 9 
grade I pilocytic astrocytomas, 15 grade II astrocytomas, 
44 grade III astrocytomas, 15 grade IV secondary GBMs, 
94 grade IV primary GBMs, 25 grade IV pediatric 
GBMs, 21 grade II oligodendrogliomas, 29 grade III 
oligodendrogliomas, 18 grade II oligoastrocytomas, 22 
grade III oligoastrocytomas, 65 medulloblastomas, 2 
pleomorphic xanthoastrocytoma, and 5 ependymomas 
were sequenced. Secondary GBM designates a GBM 
which was resected > 1 year after a prior diagnosis 
of a lower grade glioma (grade I-III). Pediatric GBM 
samples were defined if between the ages of 0-20 and 
adult GBM was classified as ages 21+. One grade 
IV GBM was not included in mutation frequency 
analyses as described below. Pilocytic astrocytomas, 
pleomorphic xanthoastrocytomas, ependymomas, and 
medulloblastomas were not considered for clinical 
analyses of grade II-IV gliomas. Median and mean ages 
reported in Table 1 was based on patients with available 
clinical information. Patients with survival of 1 month or 
less, likely due to surgical complications, were excluded 
from the survival analysis. 
Sequencing
DNA was isolated from frozen tissue and the entire 
coding sequences of ATRX, CIC, and FUBP1 were 
analyzed by Sanger sequencing [39] for 363 tumors. 1p 
and 19q copy number was determined by microsatellite 
marker analysis and mutational status of TP53, IDH1, and 
IDH2 was determined, as described previously [10]. All 
coding exons of ATRX, CIC, and FUBP1 were examined in 
363 tumors for this study. Death domain associated protein 
(DAXX) was sequenced in all grade II-III astrocytomas and 
oligodendrogliomas because it is mutated in pancreatic 
neuroepithelial tumors and pediatric GBMs [14, 31] and 
because it functions in the same telomere-regulating 
pathway as ATRX [17]. No DAXX mutations were found 
in those gliomas. ATRX mutational status (but not CIC 
or FUBP1 mutational status) for a subset of GBMs, 
medulloblastomas, and 13 oligodendrogliomas were 
reported in a previous resequencing study [13]. No grade 
II-III gliomas aside from those 13 oligodendrogliomas 
were examined for ATRX in that analysis. CIC and FUBP1 
mutational status for 7 oligodendrogliomas were reported 
in a previous whole-exome sequencing study [28]. CIC 
and FUBP1 status from other oligodendrogliomas, and for 
non-oligodendroglioma brain tumors reported here were 
not included in that analysis. Sequencing was performed 
by PCR amplification followed by Sanger sequencing as 
described previously [39].
For IDH1, IDH2, TP53, and 1p/19q status, 
sequencing efforts on an overlapping panel of 445 brain 
tumors for those alterations [10] were supplemented by 
analyzing these markers in all remaining tumors for which 
additional tumor DNA or tissue was available. IDH1 and 
IDH2 status were based on the presence or absence of 
either R132 or R172 mutations, respectively, from exon 4 
sequencing of either gene. TP53 mutational status, as well 
as 1p and 19q chromosomal status based on microsatellite 
markers, were determined as described previously [10]. 
All mutations were validated with Sanger sequencing in 
tumors and matched normal controls. One sample pGBM 
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IV-2, harbors a somatic deletion adjacent to the intron 
exon edge of ATRX and is likely to affect functionality; 
this sample was considered to have an ATRX mutation 
for the purposes of this study. Another sample, GBM-13, 
had a “hypermutator” phenotype and harbored an extreme 
number of mutations that were likely to be passenger 
mutations, as discussed in a previous exomic sequencing 
analysis [5]. This case was excluded from analyses of 
mutation frequency, mutation co-occurrence, and patient 
characteristics.
Telomere FISH, and Immunolabeling
Telomere length was assessed by FISH in 71 samples 
with available formalin-fixed, paraffin-embedded tissue, 
and p53 labeling was performed by immunofluorescence 
[13, 24, 31, 40, 41]. Loss of ATRX nuclear immunolabeling 
indicates that ATRX is inactivated by genetic or epigenetic 
changes not identifiable by sequencing of ATRX exons 
[13, 42], therefore tumors with ATRX mutation and/or loss 
of ATRX nuclear immunolabeling in tumor cells but not 
normal cells as assessed by immunohistochemistry [13] 
were considered to have an ATRX alteration. Fisher’s 
exact test was used to determine whether two aberrations 
were associated among a group of patients. 
Deparaffinized slides were hydrated, steamed for 
20 minutes in citrate buffer (catalog# H-3300; Vector 
Laboratories), dehydrated and hybridized with a Cy3-
labeled peptide nucleic acid (PNA) probe complementary 
to the mammalian telomere repeat sequence ([N-terminus 
to C-terminus] CCCTAACCCTAACCCTAA). Following 
post-hybridization washes, the desired primary antibody 
was applied (anti-ATRX, as described above), followed by 
application of species-appropriate Alexa 488 fluorescent 
secondary antibody (Molecular Probes Cat.# A-11034 or 
A-11001) and nuclear counterstaining with DAPI . Slides 
were imaged with a Nikon 50i epifluorescence microscope 
equipped with X-Cite series 120 illuminator (EXFO 
Photonics Solutions Inc., Ontario, CA) and appropriate 
fluorescence excitation/emission filters. Grayscale images 
were captured using Nikon NIS-Elements software and 
an attached Photometrics CoolsnapEZ digital camera, 
pseudo-colored and merged.
The FISH and immune-labeled slides were 
assessed and scored independently by 2 authors (C.H. 
and A.K.M.). Large, ultra-bright telomere repeat DNA 
aggregates are unique to ALT-positive cell populations 
and are significantly larger and brighter than the FISH 
signals emanating from individual telomeres in the 
same cell population (for further details, see detailed 
discussion of these foci as markers for the ALT phenotype 
in Supplementary Online Material of [13]). In this study, 
gliomas were classified as ALT-positive if they met 
the following criteria: (i) the presence of ultra-bright, 
intra-nuclear foci of telomere FISH signals, with signal 
intensities and areas for individual foci being significantly 
larger than any telomeric signals in individual benign 
cells within the same case and (ii) ≥1% of neoplastic cells 
displaying ALT-associated telomeric DNA foci. Tumor 
samples lacking ALT-associated telomeric foci in which 
at least 5000 cells were assessed were considered ALT-
negative. In all cases, areas exhibiting necrosis were 
excluded from consideration.
ATRX Immunohistochemistry
Heat-induced antigen retrieval was performed in 
a steamer using citrate buffer (catalog# H-3300, Vector 
Laboratories) for 30 minutes. Endogenous peroxidase 
was blocked (catalog# S2003, Dako) and serial sections 
were then incubated with primary antibody; anti-ATRX 
(1:400 dilution; catalog# HPA001906, Sigma-Aldrich, 
lot R00473) for 1 hour at room temperature. The primary 
antibodies were detected by 30 minute incubation with 
HRP-labeled secondary antibody (catalog# PV6119, 
Leica Microsystems) followed by detection with 
3,3′Diaminobenzidine (Sigma-Aldrich), counterstaining 
with Harris hematoxylin, rehydration and mounting. 
Only nuclear labeling of either protein was evaluated. 
The immune-labeled glioma slides were assessed 
and scored by 3 authors (R.F.W., F.R., and A.K.M.); 
internal controls included endothelial cells (including 
within intratumoral vessels), and benign neurons, which 
demonstrated strong nuclear immunolabeling for ATRX. 
29 tumors were analyzed for ATRX nuclear staining, 14 of 
which were also analyzed by sequence analysis. Tumors 
were considered to have an ATRX alteration if either a 
mutation was present when analyzed by sequencing, or 
if ATRX nuclear expression was lost when tumor tissue 
was analyzed by immunostaining, as done previously [13]. 
p53 nuclear protein immunohistochemistry was performed 
as described previously [41]. Of the 93 tumors that were 
considered to have ATRX alterations, eight tumors without 
a detectable ATRX mutation demonstrated loss of ATRX 
nuclear staining in tumor cells but not normal cells.
Survival Analysis
Survival was analyzed for adult patients (>20 years 
old at diagnosis) with grade II-IV gliomas with available 
survival and age information. 156 patients from Duke 
(Cohort A) and 43 patients from Brazil (Cohort B) met 
these criteria. A Mantel-Cox log-rank test was used to 
determine whether survival was significantly different 
between two or more groups of patients. A two-tailed 
Student’s t-test and single factor ANOVAs were used to 
determine whether mean age was significantly different 
between two or three groups of patients, respectively.  
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